Navigation Links
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Date:8/19/2007

NOVATO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that final results from the Kuvan(TM) (sapropterin dihydrochloride) pivotal Phase 3 clinical trial were published in the August 11, 2007, issue of The Lancet. The study suggests that treatment with Kuvan results in significant reductions in blood Phe levels in some phenylketonuria (PKU) patients. Kuvan, an investigational oral small molecule for the treatment of PKU, is being developed in partnership with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

"This marks the first published Kuvan clinical study, and we expect additional publications in the coming months to build on the collection of data related to Kuvan," said Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin. "We recently received priority review from the FDA and hope to receive FDA approval by late November. In the interim, we are pleased to be able to provide Kuvan to PKU patients prior to commercial availability through our expanded access program."

The Phase 3 clinical study enrolled 89 patients with elevated blood Phe levels aged eight years and above at 29 sites in the United States, Europe and Canada. All patients enrolled had demonstrated a reduction in blood Phe levels following treatment with Kuvan in a Phase 2 screening study.

The patients were randomly assigned to receive placebo or 10 mg/kg of Kuvan daily for six weeks. Patients were evaluated every two weeks for changes in blood Phe levels and adverse events. The primary objective was to assess the efficacy of Kuvan compared with placebo for reduction of blood phenylalanine in patients with PKU. The secondary objective was to assess the safety of Kuvan compared with placebo. A total of 87 patients completed six weeks of treatment.

Highlights from the Phase 3 double-blind study are summarized below:

* Patients treated with Kuvan for six weeks had a mean decrease
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN DIEGO, May 5, 2015  Trovagene, Inc. ... today reported its financial results for the three ... "In the first quarter, we presented favorable clinical ... Lung Cancer Conference, demonstrating our Precision Cancer Monitoring ... in pancreatic, colorectal, and lung cancers," said Antonius ...
(Date:5/5/2015)... , May 5, 2015 /CNW Telbec/ - Ergoresearch ... Laval and known under the « Équilibre, ... closing of the transaction previously announced on April 23, ... and outstanding  shares of Orthoconcept (2008) inc.   ... 000 common shares (TSXV: ERG) to the vending shareholder, ...
(Date:5/5/2015)... , May 5, 2015  Desert Valley Medical Center, named ... is the first U.S. hospital to deploy the wireless ... to help reduce the duration of labor and risk of ... and the risk of caesarean birth is reduced in mothers ... most mothers in labor are given epidurals and tend to ...
Breaking Medicine Technology:Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 2Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 4
... Senesco,Technologies, Inc. ("Senesco" or the "Company") (Amex: ... with VGXI, Inc. (The Woodlands, TX) ("VGXI") to,supply ... consisting,of the Factor 5A gene and siRNA against ... preclinical in vivo results,using its combination siRNA and ...
... ... Professionals, VOORHEES, N.J., July ... disease with a wide spectrum of,severity, ranging from mild diarrhea to ... of patients who develop an initial,case of CDI.(1) These patients are ...
Cached Medicine Technology:Senesco Chooses VGXI to Produce Factor 5A Plasmid 2Senesco Chooses VGXI to Produce Factor 5A Plasmid 3Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease 2
(Date:5/5/2015)... May 05, 2015 Hiliary Critchley, ... will present at the 24th Annual WEDI ... p.m. MT in Scottsdale, AZ. WEDI, the Workgroup ... nonprofit authority on the use of health IT ... Graf, National Director of Telemedicine for UnitedHealthcare will ...
(Date:5/5/2015)... 2015 From the halls of ... leader in enabling enterprise collaboration across platforms and ... speed up and simplify the move to Microsoft ... Solutions for Office 365 enable organizations to ... sustainable user adoption and effectively managing critical business ...
(Date:5/5/2015)... Sunny skies and cool temperatures made for great conditions ... and walkers participated in Global Lyme Alliance’s (GLA) inaugural ... The 5K and 10K runs and 1-and 3-mile walks were ... funds for tick-borne disease research. The “Lyme Walk and Run” ... of Lyme Research Alliance (LRA) and Tick-Borne Disease Alliance ...
(Date:5/5/2015)... May 05, 2015 " QuickPick Travel ” ... Report, which takes a look small, medium, and large businesses ... for NewsWatch and a business expert, conducted the business review ... to plan up to three weeks of vacation for free. ... and friends, and explore the world. And when people are ...
(Date:5/5/2015)... May 05, 2015 Information ... company serving the federal government, today announced its ... (CCSi). CCSi provides solutions exclusively to federal government ... experience in cyber security, health services, and program ... and industry-relevant credentials as a Third Party Assessment ...
Breaking Medicine News(10 mins):Health News:Optimity Advisors’ Hiliary Critchley, Telemedicine Expert, to Speak at WEDI Conference May 20th in Scottsdale, AZ 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 3Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 2Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 3Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4
... www.harvesttech.com ) announced today that its new patient-education website, ... offer persons who are considering enrolling in the Company’s clinical ... study’s design, the science that underlies it, and the location ... ...
... quality of care for mothers and,babies, WASHINGTON, ... for mothers and newborns the National,Quality Forum endorsed ... received by mothers and babies during the third ... quality,of care by standardizing measurement in care settings ...
... A novel topical therapy for nail fungus, NB-002, ... fungus by penetrating skin pores and diffusing through the ... a study conducted by NanoBio Corporation. , The data ... which resists topical therapies because they cannot penetrate the ...
... buy-back program expects to collect 16 tons of candy, ... consumes more,than 24 pounds of candy per year, and ... For most people, this year,s candy noshing will,simply create ... million,North Americans in orthodontic treatment, Halloween treats can pose ...
... WOODCLIFF LAKE, N.J., Oct. 28 Par,Pharmaceutical Companies, Inc. (NYSE: ... call and live webcast on Friday, November 7, 2008 at ... September 27, 2008.,The Company will release results after the market ... available on the Par website,at http://www.parpharm.com ., Access ...
... announced that despite an overall increase in news reporting ... media coverage has become significantly more negative. "How the ... breast, colorectal and prostate cancer coverage, was an independent ... analyses were issued in 2000 and 2004. The report ...
Cached Medicine News:Health News: Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 3Health News:New topical approach to treating nail fungus circumvents problems with current therapy 2Health News:Orthodontists Offer Sweet Incentives for Tricky Halloween Treats 2Health News:Orthodontists Offer Sweet Incentives for Tricky Halloween Treats 3Health News:Media coverage of lung cancer is increasing, and increasingly negative, new report shows 2
... An enzyme-linked immunosorbent assay ... detection of IgG-class antibodies to ... test is intended to be ... the diagnosis of gastrointestinal disorders, ...
... assurance reagent in assays detecting IgG and IgM ... IgM), IgG and IgM antibodies to rubella virus ... antibodies to cytomegalovirus (CMV IgG and IgM), and ... types 1 and 2 (HSV-1 IgG, HSV-1 IgM, ...
... a safe, non-surgical process that uses ... skin and reverse the signs of ... to cause collagen contraction while preserving ... addition, Titan can stimulate long-term collagen ...
... XLTEK lets you choose how to configure ... of the study to be performed we ... to your budget and clinical needs. How do ... we listen. The result? Kortex. The system that ...
Medicine Products: